Oct 13, 2022

Featuring perspectives from Dr Stephanie Lheureux, including the following topics:

• Prologue: Seminars in Cancer Biology (0:00)
• Case: A woman in her mid 50s with Stage IVB BRCA wild-type, HR-proficient primary peritoneal cancer — Dana M Chase, MD (10:54)
• Case: A woman in her mid 70s with recurrent platinum-sensitive peritoneal cancer (Lynch, VUS) and a gBRCA2 mutation— Karim ElSahwi, MD (32:33)
• Case: A woman in her early 60s with ovarian cancer and prolonged pancytopenia after treatment with a PARP inhibitor — Joseph Martins, MD (38:51)
• Case: A woman in her mid 60s with platinum-resistant recurrence of BRCA wild-type clear cell ovarian cancer after carboplatin/paclitaxel/bevacizumab and maintenance bevacizumab (homologous recombination deficiency [HRD] negative) — Neil Morganstein, MD (43:21)
• Case: A woman in her early 60s with multiregimen-recurrent BRCA wild-type, HRD-negative metastatic ovarian cancer — Rahul Gosain, MD (47:44)
• Case: A woman in her late 60s with recurrent platinum-resistant, BRCA wild-type, HR-proficient ovarian cancer after receiving paclitaxel/tumor treating fields on a clinical trial — Dr Chase (52:07)

CME information and select publications